An experienced executive, Kevin Lilly led commercialization strategies for US and global markets as senior vice president of sales at MiMedx Group, Inc. As part of his responsibilities, Kevin Lilly created development and learning programs to facilitate the sale of MiMedx's regenerative medicine products.
MiMedx recently entered a partnership with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop scientific evidence to advance effective and safe clinical therapies. In part, the collaboration seeks to further knowledge of product mechanisms of potential therapeutic targets and restore quality of life for patients through innovative biologics and regenerative science.
WFIRM has more than 400 dedicated staff members developing solutions for more than 40 organs and tissues, and has achieved multiple world firsts in transitioning scientific advancements into clinical therapies. MiMedx chief executive officer Timothy R. Wright said the collaborative agreement will provide much-needed peer-reviewed clinical data to help positively impact patient care for an array of disease states.
MiMedx recently entered a partnership with the Wake Forest Institute for Regenerative Medicine (WFIRM) to develop scientific evidence to advance effective and safe clinical therapies. In part, the collaboration seeks to further knowledge of product mechanisms of potential therapeutic targets and restore quality of life for patients through innovative biologics and regenerative science.
WFIRM has more than 400 dedicated staff members developing solutions for more than 40 organs and tissues, and has achieved multiple world firsts in transitioning scientific advancements into clinical therapies. MiMedx chief executive officer Timothy R. Wright said the collaborative agreement will provide much-needed peer-reviewed clinical data to help positively impact patient care for an array of disease states.
